Groups and subgroups (n) Trienoic conjugates, mmol/L Lipofuscin pigments, μmol/L
Before Rx After 2 months Before Rx After 2 months
1 (n=74) 12.93 ± 0.25#© 9.05 ± 0.21#©* 1.78 ± 0.05#© 1.2 ± 0.04#©*
1А (n=41) 13.66 ± 0.32©@■ 9.59 ± 0.25©*@■ 1.92 ± 0.07©@■ 1.33 ± 0.05©*@■
1B (n=33) 12.03 ± 0.35©¢® 8.38 ± 0.31©*¢® 1.59 ± 0.07©¢® 1.04 ± 0.04©*¢®
2 (n=66) 10.68 ± 0.24© 7.21 ± 0.21α* 1.41 ± 0.05© 0.97 ± 0.03©*
2А (n=15) 12.08 ± 0.53©● 8.24 ± 0.35©*● 1.63 ± 0.12©● 1.1 ± 0.07©*●
2B (n=51) 10.26 ± 0.24©¤ 6.92 ± 0.24α*¤ 1.34 ± 0.05©¤ 0.94 ± 0.03©*¤
3 (n=30) 7.05 ± 0.22 0.85 ± 0.02
# - difference significant (p<0.001) when comparing between 1 and 2 group, © - difference was significantly (p<0.05) when compared with group 3, α - difference is not significant (p>0.05) when compared with group 3, * - difference was significantly (p<0.001) when compared to treatment and after 2 months between the group (subgroup), @ - significant difference (p<0.05) when comparing between 1A and 2A subgroup, ¢ - significant difference (p<0.01) when comparing between 1B and 2B subgroup, ® - significant difference (p<0.05) when comparing between 1A and 1B subgroup, ¤ - significant difference (p<0.05) when comparing between 2A and 2B subgroup, ■ - significant difference (p<0.001) when comparing between 1A and 2B subgroup, ●- the difference is not significant (p>0.05) when comparing between the 2A and 1B subgroup
Table 1: Parameters of lipid peroxidation in patients with pulmonary tuberculosis and healthy donors (М ± m).